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Abstract
Background: The accumulation of somatic mutations in genes and molecular pathways is a major factor in the
evolution of oral squamous cell carcinoma (OSCC), which sparks studies to identify somatic mutations with clinical
potentials. Recently, massively parallel sequencing technique has started to revolutionize biomedical studies, due to
the rapid increase in its throughput and drop in cost. Hence sequencing of whole transcriptome (RNA-Seq)
becomes a superior approach in cancer studies, which enables the detection of somatic mutations and accurate
measurement of gene expression simultaneously.
Methods: We used RNA-Seq data from tumor and matched normal samples to investigate somatic mutation
spectrum in OSCC.
Results: By applying a sophisticated bioinformatic pipeline, we interrogated two tumor samples and their matched
normal tissues and identified 70,472 tumor somatic mutations in protein-coding regions. We further identified 515
significantly mutated genes (SMGs) and 156 tumor-specific disruptive genes (TDGs), with six genes in both sets,
including ANKRA2, GTF2H5, STOML1, NUP37, PPP1R26, and TAF1L. Pathway analysis suggested that SMGs were
enriched in cell adhesion pathways, which are frequently indicated in tumor development. We also found that
SMGs tend to be differentially expressed between tumors and normal tissues, implying a regulatory role of
accumulation of genetic aberrations in these genes.
Conclusions: Our finding of known tumor genes proves of the utility of RNA-Seq in mutation screening, and
functional analysis of genes detected here would help understand the molecular mechanism of OSCC.
Keywords: RNA-Seq, Oral squamous cell carcinoma, Somatic mutations, Significantly mutated genes, Differential
expression, Disruptive genes
Background
Squamous cell carcinoma is one of the most commonly
observed cancers worldwide [1], which is often diagnosed
in the oropharynx and oral cavity. It is highly invasive and
metastatic at the advanced stage, and presents a substantial
threat to human health [2]. Evidence from various mole-
cular and genetic studies suggests an association between
squamous cell carcinoma initiation and development and
the accumulation of genetic alterations at both the DNA
and RNA levels [3]. Genomic alterations such as point mu-
tations and copy number variations, epigenetic changes
such as methylation and histone modifications, as well as
gene expression changes have been previously revealed in
oral squamous cell carcinoma (OSCC), which could facili-
tate biomarker development and make clinical decisions
[3]. Among them, mutations only occurring in tumor tis-
sues, often referred as somatic mutations, are given par-
ticular attention. It is widely accepted that tumors develop
through the accumulation of somatic mutations in specific
genes, depending on their types [4]. Various studies have
found a higher than expected mutation frequency of can-
didate cancer genes, and that the tumor properties could
be influenced by different combinations of mutations [5-8].
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bal profiling of somatic mutations in OSCC, and further
understanding in mechanisms and clinical treatments.
Remarkable advances in sequencing technology over the
last several years make possible to identify genetic alter-
ations in a genome-wide scale. RNA-Seq is a newly devel-
oped deep sequencing technology, which is extensively
applied in transcriptomic profiling due to its affordable
cost. Compared with long standing methods such as
microarray, RNA-Seq gives a far more precise measure-
ment of transcript expression levels and a far more sophis-
ticated characterization of transcript isoforms [9,10].
Therefore it has been successfully applied to identify dif-
ferentially expressed genes [11] and to characterize allele-
specific expression patterns [12,13]. Moreover, it is also an
efficient and cost-effective way to study genomic alter-
ations, such as somatic mutations in transcribed regions
[14-17] or gene fusions [12-14]. Herein, we conducted a
genome-wide study to investigate the somatic mutation
spectrum in OSCC by interrogating RNA-Seq data from
two tumor samples and their matched normal samples.
We developed a sophisticated pipeline to identify somatic
mutations, and then identified significantly mutated genes
(SMG) and tumor-specific disruptive genes (TDG). By
comparing with gene expression pattern, we also found a
correlation between differentially expressed genes and
SMGs. These findings demonstrate the ability of RNA-Seq
to characterize global pattern of somatic mutations and
suggest the potential mechanism on how somatic muta-
tions could affect tumor development.
Methods
Deep sequencing data
Whole transcriptome short reads of three paired tumor
and normal tissues from patients with oral squamous cell
carcinoma (OSCC) were downloaded from European Nu-
cleotide Archive (ENA, http://www.ebi.ac.uk/ena) with the
accession number SRP002009. As described in the original
paper, the study was conducted according to the Declar-
ation of Helsinki, and was approved by the Institutional
Review Board of the Mayo Clinic [18]. Written informed
consent for the collection of samples and subsequent ana-
lysis was available for all patients. 50-bp sequence reads
were generated by using Applied Biosystems SOLiD Sys-
tem (V3 chemistry), following the manufacturer’si n s t r u c -
tions. More details can be found in the original study [18].
Sequence alignments
We first excluded low quality reads in which one or a
few bases have Q-score lower than 20. The initial quality
check suggests that all reads from one patient have an
average quality score<20 and were excluded from fur-
ther analysis. Then qualified short reads were aligned to
18,462 transcripts of UCSC consensus coding sequences
(CCDS) in current human genome assembly (hg19,
http://genome.ucsc.edu/). The alignment was carried out
using BFAST [19], using options for color-space reads.
Variant calling and identification of somatic variants
We called variants from the SAM format read align-
ments using SAMtools package [20] for each sample.
We first discarded alignments with the mapping quality
lower than 30, and then made variant calls by mpileup
and bcftools programs embedded in SAMtools [20]. To
avoid potential PCR duplicate fragments, we discarded
all variants covered by more than 500 reads, which was
achieved by setting –D as 500 when invoking vcfutils.pl
script. Several additional filters were also applied to
minimize false positive rate (Figure 1):
Filter 1 Variants were removed if they are supported
by less than two reads or mistakenly called with a
probability greater than 0.01. This was done by
requiring a value ≥ 20 for the ‘QUAL’ column in vcf
files generated by SAMtools.
Filter 2 Somatic variants were called by comparing
matched normal and tumor tissues. We first excluded
variants located in genomic regions of poor quality,
which were defined as regions with read coverage in
only one of a sample pair, probably due to randomness
in sequencing process.
Filter 3 Variants that are found in both of the matched
normal and tumor samples were discarded. Also, variants
found in dbSNP build 132 [21] were also excluded.
Identification of significantly mutated genes
To find significantly mutated genes, we adopted ap-
proaches implemented in MuSiC analysis tool suites [22].
Briefly, we counted the number of bases with at least three
read depth in six categories, including A bases, T bases,
C bases in CpG, G bases in CpG, C bases not in CpG, and
G bases not in CpG. Then the discovered mutations were
categorized as AT transitions, AT transversions, CpG
transitions, CpG transversions, CG (non-CpG) transitions,
CG transversions, and indels. Next, we calculated the
background mutation rate (BMR) for each mutation cat-
egory, which was done by dividing the total count of such
category by the total number of available bases within
such category. For indels, BMR is calculated as the total
number of bases covered by indels divided by the total
number of high quality bases. Since we used RNA-Seq
data and the read depth depends on the expression level,
tests that consider mutation coverage to identify signifi-
cantly mutated genes may not be appropriate due to
confounding factors such as allele-specific expression. In-
stead, we calculated the possibility of finding more muta-
tions than the observation for each mutation category and
combined then by the simple Fisher’s combined P-value
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can be calculated according to a χ
2 distribution with two
times the number of categories as the degrees of freedom.
Functional and pathway enrichment analysis
To identify enriched gene functions, we extracted func-
tional annotations from gene ontology (GO) [23] using
bioconductor (http://www.bioconductor.org) package “org.
Hs.eg.db”.T h e nw eu s e d“topGO” package in R software
[24] to perform hypergeometric tests. Kyoto Encyclopedia
of Genes and Genomes pathway information [25,26] was
extracted using bioconductor package “KEGG.db”,a n d
hypergeometric tests were used to identify enriched
pathways.
Differential gene expression
To estimate gene expression abundance, we counted the
number of reads that were aligned to each gene tran-
script. We then used bioconductor package “DESeq”
[27] to identify differentially expressed genes. DESeq as-
sumes a negative binomial distribution to estimate vari-
ance and mean for each group, and performs statistical
test based on it. Multiple-testing was corrected by
Benjamini and Hochberg procedure [28].
Results
Read alignments and mutation spectrum
Transcriptomes of paired normal and tumor tissues
from two OSCC patients were sequenced by Applied
Biosystems SOLiD System, and ~1,200 million short
reads were generated (200 million reads per sample),
each 50-bp long [18]. A total of 187 million reads passed
the filter and were aligned to 18,462 transcripts of UCSC
CCDS genes using BFAST aligner (Table 1). To mini-
mize possible sources of false positive in variant calling,
we only kept ~23 million aligned reads (12.4%) in total
with a minimal mapping quality score of 30. Then we
used programs in SAMtools package to call variants.
Due to the high error rate in massively parallel sequen-
cing technique and short read alignment, we took extra
care in variant identification and applied a series of
stringent filters. Finally, we identified 144,400 somatic
mutations in all samples and 70,472 of them passed all
three filters (Table 2), and both patients showed a sig-
nificant excess of somatic mutations in tumors (P<2 ×
10
-16 for patient 33 and P =5.6×10
-6 for patient 51, chi-
square test), which is expected.
Significantly mutated genes
One distinguishable feature of tumor driver genes is the
unexpectedly high somatic mutation rate, which leads to
rapid accumulation of genetic aberrations and thus rad-
ical modification or disruption of gene functions. In
hopes of finding tumor driver genes, we adopted an ap-
proach developed elsewhere [22] to identify significantly
mutated genes (SMGs). Since the number of sequencing
reads is highly variable among samples, we applied the
pipeline to each sample separately. Significantly mutated
Figure 1 Flowchart of the bioinformatics pipeline. The input data is high-quality reads in which each base has a Q-score≥20. The output file
is somatic mutations in tumor samples and was further feed into pipelines to identify significantly mutated genes (SMGs) and tumor-specific
disruptive genes (TDGs). See Methods for more details.
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base pairs covered by least three reads and have a FCPT
P-value<0.01 in the two tumor samples but not in
neither of the normal samples. In total, 515 significantly
mutated genes were identified among 11,065 genes
expressed in all samples (Additional file 1), and their aver-
age mutation rate (0.0018 per base) is significantly higher
than that of other genes (0.0008 per base, P=2. 89×10
-15).
Genes with disruptive mutations
Genes with disruptive mutations in tumor samples are
also of great interest, as they embrace the potential to
radically change gene functions. To identify disruptive
mutations, we annotated 70,472 somatic mutations iden-
tified above and searched for nonsynonymous mutations
and indels. In total, 27,310 disruptive mutations were
found in all samples (Table 2). Since our purpose was to
identify tumor-specific disruptions, we only focused on
tumor-specific disruptive genes (TDGs) which contain
disruptive mutations in the two tumor samples but not
in any normal samples. As a result, 156 genes were
found as TDGs, of which six genes were also identified
as SMGs.
Gene ontology and pathway analysis
We further performed gene ontology and pathway analysis
on both SMG and TDG sets. Although no functional cat-
egories were enriched in TDGs, we found several enriched
GO terms in SMGs (Table 3), including voltage-gated cat-
ion channel activity, intrinsic to membrane, integral to
membrane, intrinsic to plasma membrane and integral to
plasma membrane. By interrogating KEGG pathways,
we found SMGs were highly overrepresented in neuroac-
tive ligand-receptor interaction, cell adhesion molecules
(CAMs), and complement and coagulation cascades, while
TDGs were enriched in steroid biosynthesis, ribosome, and
aldosterone-regulated sodium reabsorption, at a relaxed
P-value (0.1). The difference in functions and pathways be-
tween SMGs and TDGs suggests we captured different fea-
tures of tumor in oral squamous cell carcinoma.
Somatic mutations and gene expression
To understand the potential consequence of SMGs and
TDGs, especially in gene expression, we estimated gene
expression abundance as the number of high-quality
reads mapped to each gene, and used “DESeq” to iden-
tify genes with significantly differential expression be-
tween tumors and normal samples. In total, we found 41
differentially expressed genes (DEGs) with an adjusted
P <0.05. Among them, five genes are SMGs, and one is
TDG. The number of shared genes between DEGs and
SMGs was highly unexpected (P =0.002, hypergeometric
test), while no such pattern was observed for TDGs (P =
0.07), indicating that SMGs may function through tran-
scriptional regulation.
Functional consequence of candidate genes
There are six genes (TAF1L, ANKRA2, STOML1, PPP1R26,
NUP37,a n dGTF2H5) identified in both SMGs and
TDGs, which constitute the prioritized candidates for de-
tailed functional dissection. Of them, five (TAF1L, ANKRA2,
STOML1, PPP1R26,a n dNUP37)w e r er e p o r t e di nt h e
Catalogue Of Somatic Mutations In Cancer (COSMIC,
http://www.sanger.ac.uk/genetics/CGP/cosmic/, v62 re-
lease). However, somatic mutations in GTF2H5 identified
in this study were not observed in 90 analyzed samples of
the database. GTF2H5 encodes a 71-aa peptide, which is
a subunit of the basal transcription factor TFIIH and
functions in nucleotide excision repair and transcription
[29]. To better understand the potential role of GTF2H5,
we first examined its expression pattern (Figure 2), but no
significant difference was observed between tumor and
normal tissues (P-value=1 after Benjamini-Hochberg cor-
rection), nor was its downstream gene ERCC3 (P-value =1
after Benjamini-Hochberg correction). We then predicted
the effect of the amino acid changes in GTF2H5 using
Table 1 Summary statistics of whole transcriptome sequencing data used in this study
Patient 33 Patient 51
Normal Tumor Normal Tumor
Total reads 229 M 256 M 227 M 199 M
HQ reads (%)
a 68.9 M (30.0) 47.0 M (18.3) 53.1 M (23.4) 17.8 M (9.0)
HQ mapped (%)
b 6.4 M (9.3) 4.4 M (9.3) 9.1 M (17.1) 3.4 M (18.8)
aHQ reads high-quality reads in which each base has a Q-score ≥ 20. Numbers in the brackets are percentages of high quality reads out of total reads.
bHQ mapped number of high quality reads of which mapping quality score≥30. Numbers in brackets are percentages of those mapped reads out of high quality reads.
Table 2 Summary statistics of variants or genes after
each bioinformatic filter
Patient 33 Patient 51 Sum
Normal Tumor Normal Tumor
Raw 44,185 41,645 41,970 16,600 144,400
After filter 1 33,112 31,285 34,164 13,020 111,581
After filter 2 23,869 24,950 24,636 11,811 85,266
After filter 3 20,175 21,246 20,861 8,190 70,472
Coding 9,367 10,295 8,870 3,476 32,008
Disruptive 8,058 8,827 7,590 2,835 27,310
Disruptive genes 4,454 4,758 4,404 2,076 15,692
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among these disruptive mutations. Since the major deter-
minant in oral cancers is the accumulation of genomic in-
stability [31], and no obvious evidence was observed in
radical mutations or gene expression, it is possible that the
excess of somatic mutations in GTF2H5 may influence
post-transcriptional regulation and correlate with tumor
development.
Discussion
It is well accepted that the accumulation of multiple
genetic events in different genes and molecular pathways
is the main cause of OSCC evolution [3,32]. Previous
studies have identified various types of genetic aberra-
tions in OSCCs and oral dysplasias, the precursors of
OSCCs, including somatic mutations in the D-loop of
mtDNA sequence [33] and in exons nine and 20 of
Phosphatidylinositol 3-kinase gene (PI3K) [34], common
deletions on chromosome 3p such as the 3p14 locus that
harbors FHIT (Fragile Histidine Triad) [35-37], as well as
gene copy number increases in certain oncogenes such as
EGFR and CCND1 [31,38,39]. Evidence from microarray
studies has also revealed differentially expressed genes in
oral cavity tumors [40-44], suggesting multiple dimensions
of genetic aberrations contributing to OSCC development.
Here, we presented a whole transcriptome analysis to
identify exonic somatic mutations in two OSCC samples.
To overcome the small sample size, we have developed a
stringent bioinformatic pipeline with multiple filters to re-
duce false positives. In total, we have identified 515 SMGs
which were significantly mutated, and 156 TDGs with dis-
ruptive mutations in both tumor samples. We also mea-
sured gene expression and found SMGs were enriched in
differentially expressed genes, implying that the accumula-
tion of genetic aberrations may regulate corresponding
gene expression and further affect tumor evolution.
Five of six genes identified in both SMGs and TDGs are
known driver genes in COSMIC database, and the re-
maining gene GTF2H5 stimulates the ATPase activity of
ERCC3, a nucleotide excision repair gene, to trigger DNA
opening during DNA repair. Since genes involved in DNA
repair functions are commonly associated with oral cancer
[45-47], it is very likely that GTF2H5 is also related to
carcinogenesis. Collectively, these observations indicate
our bioinformatic pipeline has substantial power to iden-
tify tumor-related genes.
Of 515 SMGs, several membrane-related GO terms
were enriched, including intrinsic to membrane, integral
to membrane, intrinsic to plasma membrane and integral
to plasma membrane. Interestingly, the original study
found that the term of intrinsic to plasma membrane was
Table 3 Enriched GO and pathway categories
Term Description Adjusted P Category
a GeneSet
b
GO:0022843 voltage-gated cation channel activity 0.019 MF SMG
GO:0031224 intrinsic to membrane 0.001 CC SMG
GO:0016021 integral to membrane 0.001 CC SMG
GO:0005887 integral to plasma membrane 0.009 CC SMG
GO:0031226 intrinsic to plasma membrane 0.011 CC SMG
HSA04080 Neuroactive ligand-receptor interaction 0.055 KEGG SMG
HSA04514 Cell adhesion molecules (CAMs) 0.052 KEGG SMG
HSA04610 Complement and coagulation cascades 0.052 KEGG SMG
HSA00100 Steroid biosynthesis 0.110 KEGG TDG
HSA03010 Ribosome 0.110 KEGG TDG
HSA04960 Aldosterone-regulated sodium reabsorption 0.110 KEGG TDG
aMF molecular function term in GO, CC cellular component term in GO, KEGG KEGG pathway terms.
bSMG significantly mutated genes, TDG tumor-specific disruptive genes (see main text for details).
Figure 2 Gene expression pattern for GTF2H5 and its
downstream gene ERCC3. The expression level was estimated by
RSEM, which counts the number of reads mapped to each transcript
and normalized by the total number of reads in each sample. No
significant difference was found between tumor and normal tissues
for each gene.
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suggesting that disruption or mis-expression of genes re-
lated to plasma membrane may be involved in tumor de-
velopment. We also found six tumor related genes,
TUSC2,TP53I3,TSSC4, RAB23, RAB39A,a n dERG,w h i c h
function as either tumor suppressor genes or oncogenes.
Additionally, we identified FGF2, a fibroblast growth fac-
tor in the FGF signaling pathway, which was reported to
be important in OSCCs [3]. Another pathway potentially
associated with OSCC is the cell adhesion molecules
(CAMs), which is also enriched in SMGs. CAMs are es-
sential component to maintain the structure of stratified
squamous epithelium and a critical mediator of tumor
progression in OSCC [48,49], and mis-expression or dys-
function of CAMs are shown to contribute to malignant
tumors [48]. The excess of CAMs in SMGs further sug-
gests the critical role of the CAM pathway in OSCCs.
Again, cell adhesion was found to be enriched in mis-
regulated genes in the original study [18], confirming that
tumor development may involve both mis-expression and
dysfunction of CAMs.
Tumor driver genes are normally considered as with
high somatic mutation rate, thus 156 TDGs identified
without information from mutation rate are intriguing. Be-
sides six genes also identified as SMGs, we also found that
57 (37%) TDGs significantly mutated in one tumor sample
but not in the other tumor sample. Considering that only
two patients were used in this study and a large proportion
of TDGs were significantly mutated in only one sample, it
is possible that some TDGs are in fact SMGs, but failed to
be identified here due to the small sample size. We thus
suggest that screening TDGs may be an alternative way to
identify candidate cancer driver genes when sample size is
limited.
Although a few pioneer studies demonstrated that
RNA-Seq is suitable for identifying somatic mutations
[14-17,50,51], there is a concern that RNA-Seq is prone to
error [15] and may generate a high false discovery rate due
to incorrect alignment of reads, sequencing errors or ex-
tremely high or low read coverage. To minimize the false
positive rate, we have applied a series of stringent filters.
First, we only used reads in which each base has a Q-score
≥ 20, which reduces the influence of sequencing errors.
Next we filtered out read alignments with a mapping qual-
ity lower than 30, which avoids reads mapped to multiple
locations alignments with low similarity. Then we required
each qualified variant must have a read depth between
three and 500. Our strategy to identify somatic mutations
also automatically removed the effect of systematically in-
correct alignments which present in both tumor and
matched samples. Hence we believe that somatic muta-
tions identified in this study provide a substantial list of
candidates for biomarker development. However, it should
also be noted that we only focused on exonic regions
captured by RNA-Seq, somatic mutations in regulatory re-
gions will not be identified here, therefore out list also pre-
sents a portion of somatic mutations in OSCCs.
Conclusions
In this study, we have developed a stringent bioinformatic
pipeline to identify somatic mutations in tumors and ap-
plied it to two OSCC paired samples. By using multiple fil-
ters and calling candidate disruptive genes through two
different ways, we minimized both false positives and false
negatives due to the small sample size. The resulting candi-
date genes with both statistical and biological significance
would help understand the molecular mechanism of OSCC
and develop clinical biomarkers and drug targets.
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